Combination immunosuppressive and anti-TNF therapy

This page covers all Combination immunosuppressive and anti-TNF therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone).

Targets

Multiple: dihydrofolate reductase (methotrexate), TNF-alpha (infliximab), glucocorticoid receptor (prednisolone)

Marketed (1)

• Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab · University of Helsinki · Immunology / Rheumatology
  This combination therapy suppresses inflammatory and immune responses through multiple mechanisms including methotrexate-induced immunosuppression, sulfasalazine's anti-inflammatory effects, corticosteroid action, and TNF-alpha inhibition via infliximab.

Patent intelligence

• combination immunosuppressive and anti tnf therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates